# US 2023/0054313 A1 · Antithrombotic compositions and methods for using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054313 A1
- Document ID: US20230054313A1
- Status: Published application
- Kind: A1
- Application number: 17/866,437
- Filed: 2022-07-15
- Published: 2023-02-23
- Earliest claimed: 2021-07-16
- Assignees: University of North Texas
- Applicants: University of North Texas
- Inventors: Pudur Jagadeeswaran
- Web page: https://patentgrep.com/patent/US20230054313A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for preventing thrombotic episodes such as venous thrombosis in patients at risk, which include estrogen-treated individuals and patients with breast cancer and lung cancer, or any individual having reduced levels of TFPI protein.

## Claims

### Claim 1

A method for decreasing the risk of, or preventing, a thrombotic event or a thrombosis (optionally venous thrombosis) in an individual in need thereof, comprising administering a compound having a formula:
or the compound UNC6852, having CAS No. 2688842-08-0,
or a salt, hydrate, solvate, tautomer, stereoisomer or deuterated isoform thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the individual in need thereof is an estrogen-treated individual, or a patient with a cancer, optionally a breast cancer or a lung cancer, or any individual having reduced levels of Tissue factor pathway inhibitor (TFPI) protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is formulated or manufactured as a parenteral formulation, an aqueous solution, a liposome, an injectable solution, a tablet, a pill, a lozenge, a capsule, a caplet, a spray, a sachet, an inhalant, a powder, a freeze-dried powder, an inhalant, a patch, a gel, a geltab, a nanosuspension, a nanoparticle, a nanoliposome, a microgel, a pellet, a suppository or any combination thereof,
and optionally the drug delivery device or product of manufacture is or comprises an implant.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is formulated or manufactured as a parenteral formulation, an aqueous solution, a liposome, an injectable solution, a freeze-dried powder, a feed, a food, a food supplement, a pellet, a lozenge, a liquid, an elixir, an aerosol, an inhalant, an adhesive, a spray, a powder, a freeze-dried powder, a patch, a tablet, a pill, a capsule, a gel, a geltab, a lozenge, a caplet, a nanosuspension, a nanoparticle, a nanoliposome, a microgel or a suppository.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is formulated in a unit dosage amount ranging from between 0.1 mg to about 1 gram, and optionally the compound is formulated as an immediate release formulation or a controlled release formulation.

### Claim 6 (depends on 1)

A kit, blister pack or package comprising a compound having a formula:
or the compound UNC6852, having CAS No. 2688842-08-0,
or a salt, hydrate, solvate, tautomer, stereoisomer or deuterated isoform thereof.
and optionally the kit comprises instructions for practicing the method of claim 1.